Abstract Number: PB0293
Meeting: ISTH 2021 Congress
Background: COVID-19 frequently associated thrombotic complication that could determine severe evolution. Inflammation was proved as important pathogenic mechanism of thrombosis.
Aims: The main objective was to evaluate the role of inflammation in increased risk of thrombosis in COVID 19 patients.
Methods: Our study was prospective and included all patients diagnosed with COVID 19 between April-September 2020 in Hematology, Pneumology and Intensive Care Unit from Colentina Clinical Hospital (285 patients). The diagnosis was established using molecular test for SARS-Cov2.
Results: Thrombotic complication was presented in 56 COVID-19 patients (19, 65%), The higher incidence of thrombosis was observed in severe form of COVID-19: stage 3 (66%) and stage 2 (26,3%), Comorbidities: diabetes mellitus, obesity and arterial hypertension were presented in majority of COVID 19 patients with thrombosis. Acute thrombosis (stroke, myocardial infarction or pulmonary embolism) was diagnosed in 14 patients; all of them were admitted in Intensive care unit due severe form of COVID-19. Inflammatory markers including C reactive protein (CRP), procalcitonin, ferritin are significantly increased in COVID-19 group with acute thrombosis compared with COVID -19 patients with thrombosis in medical history CRP 148,86mg/L (2,96-386,5) vs. 58,24mg/L (min 0,25, max 212,98) p=0,005; procalcitonin 0.93 ng/ml (0,04-784) vs 0.18 (min 0.02, max14.1) p=0.02; ferritin 702ng/ml (min102, max 4070) vs. 1195 ng/ml (min358, max12800) p=0.03. There is no significant difference between haematological parameters in COVID-19 patients with acute thrombosis or in their medical history. D Dimers are significant increased in patients with acute thrombosis 4.79 ug/ml (0.51-20) vs patients with medical history of thrombosis 2.12 (0.31-20), p=0.02. The level of protein C, protein S and antitrombine III, antiphospholipid antibodies are not significant modified in the both groups.
Conclusions: The assessment of inflammation parameters are very important in COVID-19 patients especially those with a history of thrombosis or who have significant comorbidities (diabetes mellitus, arterial hypertension or obesity).
To cite this abstract in AMA style:Popov VM, ANDREESCU M, OMER M, Popescu M, Despan C, Iliescu L, Pirvu C, Grigorie A, Niculae M, Constantin O, Rus A, Badea A, Simion I, Balea MI. The Assessment of Thrombotic Complication in Patients with COVID-19 [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/the-assessment-of-thrombotic-complication-in-patients-with-covid-19/. Accessed November 29, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-assessment-of-thrombotic-complication-in-patients-with-covid-19/